ENG/中
老虎证券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
ETF
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登录
立即注册
Toggle
港股
详情
本页面由Tiger Trade Technology Pte. Ltd.提供服务
礼邦医药-B
30.280
+4.780
18.75%
手动刷新
成交量:
127.13万
成交额:
3,713.88万
市值:
102.91亿
市盈率:
- -
高:
31.040
开:
26.900
低:
26.020
收:
25.500
52周最高:
46.820
52周最低:
22.720
股本:
3.40亿
香港流通股本:
2.27亿
量比:
0.16
换手率:
0.56%
股息:
- -
股息率:
- -
净资产收益率:
--
总资产收益率:
-33.01%
市净率:
17.69
市盈率(LYR):
- -
市销率:
291.35
数据加载中...
总览
公司
新闻
公告
概念
没有相关数据
资金流向
资金流入:
资金流出:
实时
日
周
月
季度
年
新闻
礼邦医药(09637.HK)获GIC及LAV合计增持逾132万股 涉资近5900万港元
智通财经
·
3小时前
礼邦医药(09637)获GIC及LAV合计增持逾132万股 涉资近5900万港元
智通财经
·
3小时前
港股异动 | 礼邦医药-B(09637)早盘涨超13% 短期错杀后股价快速修复 AP301商业化即将落地
智通财经
·
11小时前
异动解读|礼邦医药-B盘中上涨7.92%,报28.8港元
行情直击
·
12小时前
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/09637"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09637","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09637\",,,,,undefined,":{"symbol":"09637","market":"HK","secType":"STK","nameCN":"礼邦医药-B","latestPrice":30.28,"timestamp":1783066093492,"preClose":25.5,"halted":0,"volume":1271300,"delay":0,"changeRate":0.1874509803921569,"floatShares":227000000,"shares":339852231,"eps":0,"marketStatus":"已收盘","change":4.78,"latestTime":"07-03 16:08:13","open":26.9,"high":31.04,"low":26.02,"amount":37138772,"amplitude":0.196863,"askPrice":30.28,"askSize":200,"bidPrice":30,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-2.443,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783301400000},"marketStatusCode":5,"adr":0,"listingDate":1782662400000,"exchange":"SEHK","adjPreClose":25.5,"openAndCloseTimeList":[[1783042200000,1783051200000],[1783054800000,1783065600000]],"volumeRatio":0.162396,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09637\",,,,,undefined,":{"symbol":"09637","floatShares":227000000,"roa":"-33.01%","roe":"--","lyrEps":0,"volumeRatio":0.162396,"shares":339852231,"dividePrice":0,"high":31.04,"amplitude":0.196863,"preClose":25.5,"low":26.02,"week52Low":22.72,"pbRate":"17.69","psRate":"291.35","week52High":46.82,"institutionHeld":0,"latestPrice":30.28,"committee":-0.333333,"eps":0,"divideRate":0,"volume":1271300,"delay":0,"ttmEps":-2.443,"open":26.9,"prevYearClose":22.6,"prevWeekClose":22.6,"prevMonthClose":45.92,"prevQuarterClose":45.92,"fiveDayClose":22.6,"twentyDayClose":22.6,"sixtyDayClose":22.6},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09637\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09637\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09637\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09637\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09637","date":"2026-07-02","current":-12.394597,"percent":0.666667,"low":-18.066068,"twenty":-18.04018,"median":-14.01511,"eighty":-9.55472,"high":-8.87585,"avg":-13.743035,"sd":4.320048,"marketCap":8666231890},"quantilePoints":[{"date":"2026-06-26","current":-8.87585,"twenty":-8.87585,"median":-8.87585,"eighty":-8.87585,"marketCap":7680660420},{"date":"2026-07-02","current":-10.0073,"twenty":-18.04018,"median":-14.01511,"eighty":-9.55472,"marketCap":8666231890}],"updateTime":1783082850935},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09637\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2648668875","title":"礼邦医药(09637.HK)获GIC及LAV合计增持逾132万股 涉资近5900万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2648668875","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648668875?lang=zh_cn&edition=fundamental","pubTime":"2026-07-03 18:07","pubTimestamp":1783073222,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09637","BK1515","09939","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648668873","title":"礼邦医药(09637)获GIC及LAV合计增持逾132万股 涉资近5900万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2648668873","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648668873?lang=zh_cn&edition=fundamental","pubTime":"2026-07-03 18:07","pubTimestamp":1783073222,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,6月29日,礼邦医药(09637)获两名重要机构股东同步增持。其中,新加坡政府投资公司(GIC Private Limited)以每股44.0844港元增持87.2万股,总金额约3844.16万港元,持股增至1610.03万股,占比7.09%。同日,LAV Asset Management (Hong Kong) Limited以每股45.0615港元增持45万股,涉资约2027.78万港元,持股增至约1634.73万股,占比7.20%。两家机构合计增持逾132万股,累计投入约5872万港元,彰显出对礼邦医药长期价值的认可。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462987.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","09939","09637","BK1515","BK1161","BK4104","GIC","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648767637","title":"港股异动 | 礼邦医药-B(09637)早盘涨超13% 短期错杀后股价快速修复 AP301商业化即将落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2648767637","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648767637?lang=zh_cn&edition=fundamental","pubTime":"2026-07-03 10:05","pubTimestamp":1783044323,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,礼邦医药-B现涨超13%,截至发稿,涨10.75%,报28.24港元,成交额844.09万港元。据悉,核心产品AP301已进入NDA冲刺阶段,距商业化落地仅12-24个月窗口。值得注意的是,礼邦医药上一交易日股价出现“瀑布杀”,但剔除开盘竞价后,真正把股价砸到26港元下方的连续竞价卖单,合计不足24万股,只占全天827万股成交量的不到3%。向前看,30元为短期阻力位,一旦放量突破并站稳,可以确认修复趋势成立。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462730.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","09939","VXUS","09637","BK4588","BK1161","159938","BK4585","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145125055","title":"异动解读|礼邦医药-B盘中上涨7.92%,报28.8港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1145125055","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145125055?lang=zh_cn&edition=fundamental","pubTime":"2026-07-03 09:48","pubTimestamp":1783043322,"startTime":"0","endTime":"0","summary":"7月3日,礼邦医药-B盘中上涨7.92%,报28.8港元/股,成交额472.29万港元。礼邦医药成立于2018年,是一家专注肾脏疾病领域的生物制药企业,拥有覆盖高磷血症、肾性贫血、IgA肾病、糖尿病肾病等多适应症的产品管线。核心产品AP301为治疗高磷血症的口服磷结合剂,已完成中国III期注册临床试验,预计近期提交新药上市申请,目前正在中美推进全球III期关键多中心临床试验。公司于6月29日以22.60港元/股的发行价登陆港交所,上市首日收涨103.54%。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":6,"pageCount":1,"totalSize":23,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/09637\",params:#limit:6,delay:false,,,undefined,":[]}}